GlaxoSmithKline, in collaboration with Samsung Biologics expands production of biological medicines
GlaxoSmithKline and Samsung Biologics signed an agreement that will allow GSK to increase production of biological drugs, PharmaTimes reports.
The parties agreed that Samsung Biologics will provide GSK with additional production capacity and its amount will depend on the current needs of GSK. Transaction value of more than 231 million dollars lies for 8 years.
Initially, GSK plans to produce at the facilities of Samsung Biologics belimumab, technology transfer will start this year and the beginning of commercial production of the drug is scheduled for 2022.
